Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Roberts MJ, Conduit C, Davis ID, Effeney RM, Williams S, Martin JM, Hofman MS, Hruby G, Eapen R, Gianacas C, Papa N, Lourenço RA, Dhillon HM, Allen R, Fontela A, Kaur B, Emmett L; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Roberts MJ, et al. Among authors: hofman ms. BJU Int. 2024 Feb;133 Suppl 3:39-47. doi: 10.1111/bju.16158. Epub 2023 Sep 14. BJU Int. 2024. PMID: 37604702
Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37.
Papa N, Perera M, Hofman MS, Bolton D, Lawrentschuk N. Papa N, et al. Among authors: hofman ms. Eur Urol. 2017 Feb;71(2):e66-e67. doi: 10.1016/j.eururo.2016.08.050. Epub 2016 Sep 3. Eur Urol. 2017. PMID: 27597236 No abstract available.
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.
Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A. Fanti S, et al. Among authors: hofman ms. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1622-1635. doi: 10.1007/s00259-017-3725-1. Epub 2017 May 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28536833
A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N. Hofman MS, et al. BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3. BJU Int. 2018. PMID: 29726071 Clinical Trial.
286 results